| Value | ₹3,952 Cr |
|---|
BSE filing, NSE: SHRIRAMFIN. Summary written from the filing by ALFA Finder's alert engine.
Shriram Finance Ltd: key numbers
- Share price
- ₹823.15
- Market cap
- ₹1,93,694 Cr
- Revenue (annual)
- ₹48,133 Cr
- Net profit (annual)
- ₹10,024 Cr
- P/E (TTM)
- 15.3×Sector 19.1×
- Promoter holding
- 20.30%+0.00% QoQ
- FII holding
- 55.65%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shriram Finance Ltd
All →Shriram Finance Annual General Meeting
Shriram Finance sent a postal ballot notice seeking approval to issue up to Rs.35,000 Crore of private placement debentures. Voting runs 31 October to 29 November 2026.
- Value
- ₹35,000 Cr
- Execution
- One year from the date of passing of the resolution
Shriram Finance Debt & Borrowing: ₹6.75 Cr
Shriram Finance paid Rs 6.75 Crore of interest on its NCDs on 29 October 2026, on time. This is a Regulation 57 confirmation of a debt servicing payment.
- Value
- ₹6.75 Cr
Shriram Finance Debt & Borrowing: ₹10.72 Cr
Shriram Finance confirmed timely payment of ₹10.72 Crore interest on NCDs (ISIN INE721A07SP0). Routine debt-servicing certification under Reg 57.
- Value
- ₹10.72 Cr
Shriram Finance Debt & Borrowing: ₹60.03 Cr
Shriram Finance paid Rs 4,121.60 lakh and Rs 1,881.25 lakh interest on NCDs and subordinated debt. Routine debt servicing with no new capital raised.
- Value
- ₹60.03 Cr
Shriram Finance Other Announcement
Shriram Finance filed CRISIL's quarterly monitoring report on preferential issue proceeds for Q2 FY27. Proceeds were utilized towards onward lending with no deviation from objects.
Shriram Finance Earnings Call Transcript: Key Takeaways
Shriram Finance delivered strong profit growth despite seasonal headwinds, though asset quality in drought-prone regions saw a temporary uptick. Management maintains a cautious but optimistic outlook for the busy second half.
- Call
- Guides 17% growth
Other fund raise announcements
All →Sudarshan Pharma Industries Fund Raise of ₹72 Cr
Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.
- Value
- ₹72.00 Cr
Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr
Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.
- Value
- ₹68.20 Cr
Kanel Industries Fund Raise of ₹16.99 Cr
Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.
- Value
- ₹16.99 Cr
- Execution
- Rights issue opens 23 November 2026 and closes 30 November 2026
Sudarshan Pharma Industries Fund Raise
Board approved issuing up to 72 Crore warrants to promoters on a preferential basis. Pricing per Reg 164 is pending, with no fixed rupee value stated.
GAIL (India) Fund Raise
GAIL Board approved in principle the IPO of subsidiary GAIL Gas Limited on Indian exchanges. GAIL will dilute its GGL equity up to 25%.
Gujarat Inject (Kerala) Fund Raise of ₹3 Cr
Gujarat Inject Kerala's board approved a Rs.3 Crore preferential warrant issue to public investors. Authorised capital will rise to Rs.17.63 Crore, subject to shareholder approval.
- Value
- ₹3.00 Cr